Drug Approval | November 06, 2025
Bayer's finerenone approved in India for heart failure
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Subscribe To Our Newsletter & Stay Updated
